DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT05872620

ATTAIN-2

CompletedPhase 3

A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes

A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2)

Asset

Orforglipron

Oral · GLP-1 agonist

Listed sites

136

Recruiting sites

—

Enrollment

1,613

actual

Study population

Obesity / overweight, Type 2 diabetes

Key I/E criteria

•BMI ≥27•HbA1c ≥7%

Primary endpoint

•Body weight, % change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05872620
Org study ID18560
Secondary ID2022-502837-24-00Eli Lilly and Company
Secondary IDJ2A-MC-GZGQEli Lilly and Company
Secondary IDU1111-1289-8799UTN Number

Timeline

Milestones

Study first posted2023-05-24actual
Study start2023-06-05actual
Primary completion2025-08-08actual
Study completion2025-08-08actual
Last update posted2025-09-18actual

Assets

Investigational agents

Orforglipron

Study populations

Who this study enrolls

Obesity / overweightType 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Have a body mass index (BMI) ≥27.0 kilogram/square meter (kg/m²).
•Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight.
•Have a diagnosis of Type 2 Diabetes (T2D), with HbA1c ≥7% (≥53 mmol/mol) to ≤10% (86 mmol/mol) and are on stable treatment for T2D for at least 90 days prior to screening, consisting of:
–either diet/exercise alone or
–up to 3 oral antihyperglycemic medications (excluding dipeptidyl peptidase IV inhibitors (DPP-4i) or glucagon-like peptide-1 (GLP-1) receptor agonists (RA).

Exclusion criteria

•Have Type 1 Diabetes (T1D), history of ketoacidosis or hyperosmolar state/coma, or any other types of diabetes except T2D.
•Have a self-reported change in body weight >5 kg (11 pounds) within 90 days prior to screening.
•Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema (for example, laster photocoagulation or intravitreal injections of anti-vascular endothelial growth factor inhibitors).
•Have family (first-degree relative) or personal history of medullary thyroid cancer (MTC) or multiple endocrine neoplasia 2 (MEN2) syndrome.
•Have had a history of chronic or acute pancreatitis.

Endpoints (10)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Cardiometabolic biomarkers
4
Glycemic / diabetes
3
Weight & body composition
2
Patient-reported / QoL
1

Weight & body composition

2 endpoints
Primary/protocol endpoint

Mean Percent Change from Baseline in Body Weight

Time frame:Baseline, Week 72

Body weight, % change

percent change from baseline, improvement

Secondary/protocol endpoint

Mean Change from Baseline in Waist Circumference

Time frame:Baseline, Week 72

Waist circumference, change

change from baseline, improvement

Glycemic / diabetes

3 endpoints
Secondary/protocol endpoint

Mean Change from Baseline in Hemoglobin A1c (HbA1c) %

Time frame:Baseline, Week 72

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

Mean Change from Baseline in Fasting Glucose

Time frame:Baseline, Week 72

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Secondary/protocol endpoint/low confidence

Mean Percent Change from Baseline in Fasting Insulin

Time frame:Baseline, Week 72

percent change from baseline, improvement

Cardiometabolic biomarkers

4 endpoints
Secondary/protocol endpoint

Mean Change from Baseline in Systolic Blood Pressure (SBP)

Time frame:Baseline, Week 72

Systolic BP, change

change from baseline, improvement

LOINC 8480-6

Secondary/protocol endpoint

Mean Change from Baseline in Fasting Triglycerides

Time frame:Baseline, Week 72

Triglycerides, change

change from baseline, improvement

LOINC 2571-8

Secondary/protocol endpoint

Mean Percent Change from Baseline in Fasting non-High-Density Lipoprotein (HDL) Cholesterol

Time frame:Baseline, Week 72

Non-HDL cholesterol, change

percent change from baseline, improvement

Secondary/protocol endpoint

Mean Change from Baseline in Diastolic Blood Pressure (DBP)

Time frame:Baseline, Week 72

Diastolic BP, change

change from baseline, improvement

LOINC 8462-4

Patient-reported / QoL

1 endpoint
Secondary/protocol endpoint

Mean Change from Baseline in Short Form 36 Version 2 Health Survey Acute Form (SF-36v2) Domain Scores

Time frame:Baseline, Week 72

change from baseline, improvement

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.